Try our Advanced Search for more refined results
Life Sciences
-
March 19, 2026
4th Circ. Leery Of W.Va. Opioid Towns' Abatement Arguments
During a heated hourlong oral argument Thursday, two Fourth Circuit judges interrogated an attorney for West Virginia municipalities stricken by the opioid crisis about whether the public nuisance of overly available drugs had already been abated, leaving only redress of resulting harms.
-
March 19, 2026
Chan Zuckerberg Initiative Hit With Gender Bias Action
The Chan Zuckerberg Initiative LLC run by Meta Platforms Inc. CEO Mark Zuckerberg and his wife Priscilla Chan discriminated against women by routinely paying them less than men and promoting them with less frequency, according to a proposed class and collective action removed Wednesday to California federal court.
-
March 19, 2026
Pharma Group Can't Halt Colo. Law Over Drug Discount Rules
A Colorado federal judge denied a bid by the Pharmaceutical Research and Manufacturers of America seeking to halt enforcement of a state law guarding providers' ability to contract with pharmacies to distribute discounted drugs under the federal 340B program.
-
March 19, 2026
Apple Watch Redesign Gets Early OK As Patent Loss Upheld
The Federal Circuit on Thursday affirmed a U.S. International Trade Commission decision that found a previous version of the Apple Watch infringes two Masimo blood oxygen monitor patents, but the ruling came one day after an ITC judge said Apple's redesigned version does not infringe those patents.
-
March 19, 2026
Legislative Update: Cannabis And Psychedelics Bill Roundup
Virginia lawmakers last week gave final approval to legislation that would tax and regulate the sale of adult-use cannabis, Georgia legislators passed a dramatic expansion of the state's medical cannabis program, and Iowa lawmakers approved a bill to designate kratom as a Schedule I substance. Here are the major moves in cannabis and psychedelics legislation from the past week.
-
March 19, 2026
Drug Co. Can't Claim Most Docs Contain Trade Secrets At Trial
A Manhattan federal judge ruled Thursday that a pharmaceutical consulting company won't be allowed to argue to a jury that thousands of documents it did not enter into evidence contain trade secrets amid an ongoing misappropriation trial.
-
March 19, 2026
Still No Shenanigans: Fed. Circ. Keeps Review Bar High
The Federal Circuit's rejection of all mandamus petitions asking it to rein in the way U.S. Patent and Trademark Office leadership is evaluating patent challenges cements the appeals court's near-impossible standard for reviewing institution decisions, attorneys say.
-
March 19, 2026
Calif. Families Sue Rady Health Over Move To End Trans Care
Four families have asked a state judge to prevent California's largest pediatric health system from cutting off gender-affirming care for minors, alleging the move would violate state antidiscrimination laws and leave them scrambling to find new providers, some more than 100 miles away.
-
March 19, 2026
Goodwin, S&C Steer Up To $785M Sale Of ADHD Drug
Goodwin Procter LLP-advised Collegium Pharmaceutical Inc. unveiled plans Thursday to acquire attention deficit hyperactivity disorder drug Azstarys from Sullivan & Cromwell LLP-led Corium Therapeutics Holdings LLC for up to $785 million.
-
March 19, 2026
CVS, Caremark Pocket Money Meant For Rebates, Suit Claims
CVS charges drug manufacturers "exorbitant" fees in exchange for pushing their products, then pockets the money instead of funneling it toward customer rebates as it promises, a federal lawsuit alleges, accusing the company of collecting billions of dollars at customers' expense and violating the anti-racketeering statute.
-
March 19, 2026
Zynex Gets OK For Ch. 11 Plan Reducing Debt By $50M
Zynex Inc., a pain management medical device maker, received confirmation Thursday of its Chapter 11 plan, which reduces its debt by about $50 million and turns over the company to its creditors.
-
March 18, 2026
Key Details As 3rd Circ. Ponders FCA's Fate, $1.6B J&J Fine
Third Circuit judges Wednesday explored divergent views of the False Claims Act's constitutionality and a record fraud verdict against Johnson & Johnson, expressing little eagerness to gut the FCA's whistleblower mechanism, and voicing uncertainty about evidence and jury instructions underpinning the drug promotion punishment.
-
March 18, 2026
Apple Took Masimo IP But No Remedy Warranted, Judge Says
A California federal judge determined Apple misappropriated two out of five of Masimo Corp.'s asserted trade secrets related to pulse oximetry technology for its smartwatches, but found Masimo's requests for an injunction and attorney fees unwarranted, according to a December bench trial ruling that was unsealed this week.
-
March 18, 2026
Stryker Hit With Another Suit After Cyberattack
Another proposed class action has been filed against Michigan-based medical technology company Stryker Corp. in the wake of a March 11 cyberattack on the company that was reportedly perpetrated by hackers tied to Iran.
-
March 18, 2026
FINRA Says Compliance Chief Took Part In Pre-IPO Fraud
The Financial Industry Regulatory Authority has alleged in a disciplinary proceeding that Spartan Capital Securities LLC, its CEO and chief compliance officer defrauded customers by liquidating their own pre-initial public offering shares of a pharmaceutical company more quickly and at a higher price than their customers.
-
March 18, 2026
Squires' Latest Order Grants 9 Patent Reviews, Spurns 6
A new bulk order from the U.S. Patent and Trademark Office director on America Invents Act patent challenges denied six petitions and granted nine others, bringing the total number of institution decisions he's made since October past 400.
-
March 18, 2026
Abbott Investors Ink $40M Deal Over Infant Formula Crisis
Shareholders who brought a derivative suit over Abbott Laboratories' management of the 2022 infant formula crisis asked an Illinois judge on Tuesday to approve a settlement that includes $40 million in investments in food safety and corporate reforms, and $15.85 million in attorney fees.
-
March 18, 2026
USPTO Wants 900 New Patent Examiners By October
The U.S. Patent and Trademark Office plans to hire 900 patent examiners focusing on sciences and engineering by Oct. 1, two agency managers said in a Wednesday webinar.
-
March 18, 2026
NC Judge Moves Ex-Exec's Wage Fight With Cancer Co. To Va.
A North Carolina federal judge agreed to transfer a former C-suite executive's unpaid wages case against a Canadian cancer testing and treatment company to Virginia, where its U.S. headquarters are, finding the Old Dominion is the better venue.
-
March 18, 2026
Food Cos. Get Another Shot At David Protein Antitrust Case
A New York federal court is letting low-calorie food producers take another shot at their antitrust claims accusing protein bar-maker David Protein of refusing to sell them a fat replacement ingredient after purchasing the ingredient's only supplier.
-
March 18, 2026
DLA Piper Lands Shook Hardy Products Liability Pro In Miami
A longtime Shook Hardy & Bacon LLP trial lawyer specializing in high-stakes product liability and complex litigation has joined DLA Piper in Miami, the firm announced Wednesday.
-
March 18, 2026
Axion Cleared Of False Advertising Before Agilent Patent Trial
Ahead of a patent infringement trial set to begin next week, a Delaware federal judge has addressed false advertising claims against biotechnology firm Axion and ruled there was no genuine dispute that a set of Axion advertisements deceived customers.
-
March 18, 2026
Biotech Investor Blames Pierce Atwood For Messy Asset Sale
A Ukrainian billionaire who was recently ordered to pay other investors in a failed genetic testing company more than $1.8 million in damages is blaming the Pierce Atwood LLP lawyers who advised him on what a court later found to be a "fundamentally unfair" forced asset sale.
-
March 18, 2026
Latham Hires Desmarais IP Partner In DC
Latham & Wakins LLP has hired a Desmarais LLP partner in D.C., who helped represent GlaxoSmithKline Biologicals in an ongoing infringement suit against Moderna Inc., the firm announced Tuesday.
-
March 17, 2026
Pot Co. Escapes Potency Suit, Judge Warns Plaintiff Firm
MariMed and other cannabis companies beat claims they intentionally mislabeled their products to sidestep Illinois THC potency limits, with a federal judge highlighting the string of consumer-led suit losses and warning counsel to "heed the strong and universal concerns about the plausibility of their legal theories."
Expert Analysis
-
4 Ways GCs Can Manage Growing Service Of Process Volume
As automation and arbitration increase the volume of legal filings, in-house counsel must build scalable service of process systems that strengthen corporate governance and manage risk in real time, says Paul Mathews at Corporation Service Co.
-
Series
The Law Firm Merger Diaries: Forming Measurable Ties
Relationship-building should begin as early as possible in a law firm merger, as intentional pathways to bringing people together drive collaboration, positive client response, engagements and growth, says Amie Colby at Troutman.
-
AG Watch: Va. Insulin Price Probe Signals Rising Scrutiny
Virginia Attorney General Jason Miyares' recent investigation into insulin manufacturers and pharmacy benefit managers for allegedly colluding to artificially inflate insulin prices reflects a broader trend to leverage consumer protection authority in high-impact healthcare matters, and the upcoming leadership change is unlikely to diminish scrutiny in this area, says Chuck Slemp at Cozen O'Connor.
-
FDA's AI Deployment Brings New Potential And Risks
The U.S. Food and Drug Administration's recent announcement about making agentic artificial intelligence tools available to agency employees may portend accelerated regulatory timelines and lower costs for drug companies and consumers, but potential errors and biases will necessitate additional safeguards, says Angela Silva at Lewis Brisbois.
-
3 Key Takeaways From Planned Rescheduling Of Cannabis
An executive order reviving cannabis rescheduling represents a monumental change for the industry and, while the substance will remain illegal at the federal level, introduces several benefits, including improving state-legal cannabis operators' tax treatment, lowering the industry's legal risk profile, and leaving state-regulated markets largely intact, say attorneys at Dentons.
-
6 Issues That May Follow The 340B Rebate Pilot Challenge
Though the Health Resources and Services Administration withdrew a pending case to reconsider the controversial 340B rebate pilot program, a number of crucial considerations remain, including the likelihood of a rework and questions about what that rework might look like, say attorneys at Spencer Fane.
-
5 E-Discovery Predictions For 2026 And Beyond
2026 will likely be shaped by issues ranging from artificial intelligence regulatory turbulence to potential evidence rule changes, and e-discovery professionals will need to understand how to effectively guide the responsible and defensible adoption of emerging tools, while also ensuring effective safeguards, say attorneys at Littler.
-
Streamlining Product Liability MDLs With AI And Rule 16.1
With newly effective Rule 16.1 of the Federal Rules of Civil Procedure providing enhanced guidance on multidistrict litigation and the sophistication of artificial intelligence continuing to advance, parties have the opportunity to better confront the significant data challenges presented by product liability MDLs, say attorneys at Hollingsworth.
-
Business Considerations Amid Hemp Product Policy Change
With the passage of a bill fundamentally narrowing the federal definition of "hemp," there are practical and business considerations that brands, manufacturers and other parties should heed over the next year, including operational strategies, evaluating contract and counterparty risk, and tax implications, say attorneys at Foley Hoag.
-
Series
Judges On AI: How Courts Can Boost Access To Justice
Arizona Court of Appeals Judge Samuel A. Thumma writes that generative artificial intelligence tools offer a profound opportunity to enhance access to justice and engender public confidence in courts’ use of technology, and judges can seize this opportunity in five key ways.
-
Fed. Circ. In November: Looking For Patent 'Blaze Marks'
The Federal Circuit's recent decision in Duke v. Sandoz serves as a warning that when patentees craft claims, they must provide adequate "blaze marks" that direct a skilled artisan to the specific claimed invention, and not just the individual claimed elements in isolation, say attorneys at Knobbe Martens.
-
2025's Most Notable State AG Activity By The Numbers
State attorneys general were active in 2025, working across party lines to address federal regulatory gaps in artificial intelligence, take action on consumer protection issues, continue antitrust enforcement and announce large settlements on behalf of their citizens, say attorneys at Jenner & Block.
-
Opinion
The Case For Emulating, Not Dividing, The Ninth Circuit
Champions for improved judicial administration should reject the unfounded criticisms driving recent Senate proposals to divide the Ninth Circuit and instead seek to replicate the court's unique strengths and successes, says Ninth Circuit Judge J. Clifford Wallace.
-
How Rule 16.1 Streamlines And Validates Mass Tort Litigation
The new Rule 16.1 of the Federal Rules of Civil Procedure not only serves a practical purpose by endorsing early, structured case management and dispositive motion practice in multidistrict litigation, but also explicitly affirms the importance of MDL practice in the justice system, says Rocco Strangio at Milestone.
-
How 11th Circ.'s Zafirov Decision Could Upend Qui Tam Cases
Oral argument before the Eleventh Circuit last month in U.S. ex rel. Zafirov v. Florida Medical Associates suggests that the court may affirm a lower court's opinion that the qui tam provisions of the False Claims Act are unconstitutional — which could wreak havoc on pending and future qui tam cases, say attorneys at Morgan Lewis.